Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEAK: Almonertinib + Palbociclib in KRAS-mutant Advanced Solid Tumors
ChiCTR2500101627Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of almonertinib and palbociclib in Nonhematologic neoplasms (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Safety and Objective Response Rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
almonertinibpalbociclib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500101627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101627.